SCHEMBL393047

SCHEMBL393047

Cc1[nH]c(C=C2C(=O)Nc3cc(NC(=O)c4ccc(CN5CCN(C)CC5)cc4)ccc32)c(C)c1C(=O)NCCN(C)C

nearest known ligand 0.61

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
NTRK2 Q16620 1/20 0.61
RET P07949 1/20 0.61
PRKAA1 Q13131 8/20 0.57
KDR P35968 8/20 0.57
PRKAA2 P54646 7/20 0.57
PDGFRB P09619 4/20 0.57
FGFR1 P11362 3/20 0.57
FLT3 P36888 4/20 0.57
AURKB Q96GD4 3/20 0.57
MET P08581 1/20 0.57
CSF1R P07333 3/20 0.55
KIT P10721 2/20 0.52
EGFR P00533 1/20 0.52
NEK2 P51955 1/20 0.52
MELK Q14680 1/20 0.52
AURKA O14965 1/20 0.52
LCK P06239 1/20 0.52
KCNH2 Q12809 1/20 0.52
TLK2 Q86UE8 1/20 0.52

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10091865 1.00 NTRK2 (0.61) NTRK2RETPRKAA1KDRPRKAA2
SCHEMBL393782 0.96 NTRK2 (0.64) NTRK2RETPRKAA1KDRPRKAA2
SCHEMBL10091883 0.96 NTRK2 (0.64) NTRK2RETPRKAA1KDRPRKAA2
SCHEMBL10091874 0.93 PRKAA1 (0.66) NTRK2RETPRKAA1KDRPRKAA2
SCHEMBL398743 0.93 PRKAA1 (0.66) NTRK2RETPRKAA1KDRPRKAA2
SCHEMBL398199 0.92 KDR (0.68) NTRK2RETPRKAA1KDRPRKAA2
SCHEMBL10091884 0.92 KDR (0.68) NTRK2RETPRKAA1KDRPRKAA2
SCHEMBL10091878 0.89 CSF1R (0.63) NTRK2RETPRKAA1KDRPRKAA2
SCHEMBL395938 0.89 CSF1R (0.63) NTRK2RETPRKAA1KDRPRKAA2
SCHEMBL4143548 0.89 RET (0.67) NTRK2RETKDRPDGFRBFGFR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8101608-B2 3-(4-Methyl-imidazol-1-yl)-N-{3-[2-oxo-3-(1H-pyrrol-2-ylmethylene)-2,3-dihydro-1H-indol-6-ylamino]-phenyl}-5-trifluoromethyl-benzamide; including benign and malignant proliferative disorders as well as diseases resulting from inappropriate activation of the immune and nervous systems IRM LLC, a Delware Limited Corporation (BM) 2012-01-24 US claimed
US-8101608-B2 3-(4-Methyl-imidazol-1-yl)-N-{3-[2-oxo-3-(1H-pyrrol-2-ylmethylene)-2,3-dihydro-1H-indol-6-ylamino]-phenyl}-5-trifluoromethyl-benzamide; including benign and malignant proliferative disorders as well as diseases resulting from inappropriate activation of the immune and nervous systems IRM LLC, a Delware Limited Corporation (BM) 2012-01-24 US disclosed